Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 studyMakoto Ueno, Junji Furuse, Satoshi Kobayashi et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 331